Fig. 1

Overview of asparaginase treatment scenarios in the decision-tree model. Two scenarios were modelled, according to potential clinical options for first-line and second-line (in case of hypersensitivity) asparaginase treatment in the UK. Current therapy strategy: pegaspargase followed by Erwinia asparaginase. Old therapy strategy: native asparaginase followed by Erwinia asparaginase. ALL, acute lymphoblastic lymphoma; AYA, adolescents and young adults; EFS, event-free survival; HR, high risk; HS, hypersensitivity; IR, intermediate risk; R/ST, relapse/secondary tumor; SR, standard risk; y, year